BLUEBIRD BIO INC (BLUE) Stock Price, Quote, News and Overview
NASDAQ:BLUE - Nasdaq - US09609G1004 - Common Stock - Currency: USD
BLUE Quote, Performance and Key Statistics
4.08
-2.96 (-42.05%)
The current stock price of BLUE is 4.08 USD. In the past month the price decreased by -48.16%. In the past year, price decreased by -83.68%.
BLUE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BLUE
Company Profile
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. The company is headquartered in Somerville, Massachusetts and currently employs 375 full-time employees. The company went IPO on 2013-06-19. The firm is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. The company markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). The company is focused on pursuing curative gene therapies.
Company Info
BLUEBIRD BIO INC
455 Grand Union Boulevard
Somerville MASSACHUSETTS 02142 US
CEO: Nick Leschly
Employees: 375
Company Website: https://www.bluebirdbio.com/
Investor Relations: https://investor.bluebirdbio.com
Phone: 13394999300
BLUEBIRD BIO INC / BLUE FAQ
What is the stock price of BLUEBIRD BIO INC today?
The current stock price of BLUE is 4.08 USD. The price decreased by -42.05% in the last trading session.
What is the ticker symbol for BLUEBIRD BIO INC stock?
The exchange symbol of BLUEBIRD BIO INC is BLUE and it is listed on the Nasdaq exchange.
On which exchange is BLUE stock listed?
BLUE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BLUEBIRD BIO INC stock?
15 analysts have analysed BLUE and the average price target is 37.01 USD. This implies a price increase of 807.14% is expected in the next year compared to the current price of 4.08. Check the BLUEBIRD BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BLUEBIRD BIO INC worth?
BLUEBIRD BIO INC (BLUE) has a market capitalization of 39.66M USD. This makes BLUE a Nano Cap stock.
How many employees does BLUEBIRD BIO INC have?
BLUEBIRD BIO INC (BLUE) currently has 375 employees.
Is BLUEBIRD BIO INC (BLUE) expected to grow?
The Revenue of BLUEBIRD BIO INC (BLUE) is expected to grow by 74.73% in the next year. Check the estimates tab for more information on the BLUE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BLUEBIRD BIO INC (BLUE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLUE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLUE, evaluating the profitability, health, valuation and growth aspects
- BLUEBIRD BIO INC (BLUE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BLUEBIRD BIO INC (BLUE) Sales and EPS estimates to see what analysts future expectations are.
- BLUEBIRD BIO INC (BLUE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BLUEBIRD BIO INC (BLUE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BLUEBIRD BIO INC (BLUE) Stock Chart to make your own analysis
- BLUEBIRD BIO INC (BLUE) Latest news and press-releases to stay up to date.
Does BLUEBIRD BIO INC (BLUE) stock pay dividends?
BLUE does not pay a dividend.
When does BLUEBIRD BIO INC (BLUE) report earnings?
BLUEBIRD BIO INC (BLUE) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of BLUEBIRD BIO INC (BLUE)?
BLUEBIRD BIO INC (BLUE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.65).
What is the Short Interest ratio of BLUEBIRD BIO INC (BLUE) stock?
The outstanding short interest for BLUEBIRD BIO INC (BLUE) is 26.25% of its float. Check the ownership tab for more information on the BLUE short interest.
BLUE Technical Analysis
BLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BLUE. BLUE may be in some trouble as it scores bad on both profitability and health.
BLUE Financial Highlights
Over the last trailing twelve months BLUE reported a non-GAAP Earnings per Share(EPS) of -22.65. The EPS decreased by -2960.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BLUE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to BLUE. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 35.36% and a revenue growth 74.73% for BLUE